SCHEMBL4907682

SCHEMBL4907682

COc1ccccc1N1CCN(CCCCN(C(N)=O)c2ccc3nccn3c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.53
DRD3 P35462 4/20 0.53
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HTR1A P08908 1/20 0.48
DRD4 P21917 1/20 0.48
HTR7 P34969 2/20 0.48
ADRA1A P35348 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3618645 0.79 DRD2 (0.68) DRD2DRD3KDM4EALDH1A1TDP1
SCHEMBL4906839 0.78 DRD2 (0.62) DRD2DRD3KDM4EALDH1A1TDP1
SCHEMBL4915589 0.78 DRD2 (0.50) DRD2DRD3KDM4EALDH1A1TDP1
SCHEMBL5468144 0.77 ALDH1A1 (0.53) DRD2KDM4EALDH1A1TDP1MEN1
SCHEMBL4918606 0.76 KDM4E (0.51) DRD2DRD3KDM4EALDH1A1TDP1
SCHEMBL4916834 0.75 DRD2 (0.58) DRD2DRD3KDM4EALDH1A1TDP1
Hydrochloric Acid SCHEMBL19580067 0.75 DRD3 (0.62) DRD2DRD3KDM4EALDH1A1TDP1
SCHEMBL4915564 0.75 DRD2 (0.53) DRD2DRD3KDM4EALDH1A1TDP1
SCHEMBL4908005 0.75 DRD2 (0.53) DRD2DRD3KDM4EALDH1A1TDP1
SCHEMBL4916690 0.75 MEN1 (0.49) DRD2DRD3KDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778685-B1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-26 EP claimed
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof SCHWARZ PHARMA AG (DE) 2008-02-28 US claimed
EP-1778685-A1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SCHWARZ PHARMA AG (DE) 2007-05-02 EP claimed
WO-2006015737-A1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SCHWARZ PHARMA AG (DE) 2006-02-16 WO claimed
EP-1778685-B1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-26 EP disclosed
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof SCHWARZ PHARMA AG (DE) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof GRIN2A, GRIN2C, GRIN1 DRD2 248/4885DRD3 474/4885KDM4E 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.